TSCAN THERAPEUTICS INC
NASDAQ: TCRX (TScan Therapeutics, Inc.)
Kemas kini terakhir: 7 jam lalu0.381
-0.29 (-42.80%)
| Penutupan Terdahulu | 0.666 |
| Jumlah Dagangan | 8,401,542 |
| Harga / Jualan (P/S) | 12.15 |
| Harga / Buku (P/B) | 0.650 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -1,669.74% |
| EPS Cair (TTM) | -1.08 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 283.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 46.16% |
| Nisbah Semasa (MRQ) | 8.55 |
| Aliran Tunai Operasi (OCF TTM) | -119.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -77.27 M |
| Pulangan Atas Aset (ROA TTM) | -30.45% |
| Pulangan Atas Ekuiti (ROE TTM) | -78.93% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | TScan Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.23% |
| % Dimiliki oleh Institusi | 88.08% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Baker Bros. Advisors Lp | 30 Jun 2026 | 2,784,792 |
| Deer Management Co. Llc | 30 Jun 2026 | 1,245,504 |
| Jacobs Levy Equity Management, Inc | 30 Jun 2026 | 1,049,806 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |